|
1) Jono S, Mckee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000; 87: E10
|
|
|
|
2) National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42: S1
|
|
|
|
|
|
3) 日本透析医学会, 編. 透析患者における二次性副甲状腺機能亢進症治療ガイドライン. 2006
|
|
|
|
|
|
4) Guerin AP, London GM, Marchais SJ, et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000; 15: 1014
|
|
|
|
|
5) Chertow GM, Burke SK, Paggi P, et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245
|
|
|
|
|
|
6) Koiwa F, Onoda N, Kato H, et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial. 2005; 9: 340
|
|
|
|
|
7) Iwasaki Y, Takami H, Tani M, et al. Efficency of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients. Ther Apher Dial. 2005; 9: 347
|
|
|
|
|
|
8) Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney International. 2007; 71: 438
|
|
|
|
|
|
9) Sigematsu T. The Lanthanum Carbonate Reseach Group. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial. 2008; 12: 55
|
|
|
|
|
|
10) Shigematsu T. Lanthanum Carbonate Group. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol. 2008; 70: 404
|
|
|
|
|
|
11) DʼHaese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate(Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl. 2003; 85: S73
|
|
|
|
|
|
12) Wilson R, Zhang P, Smyth M, et al. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Med Res Opin. 2009; 25: 3021
|
|
|
|
|
|
13) Shigematsu T, Lanthanum Carbonate Group. Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients. Clin Exp Nephrol. 2010. Sep 4[Epub ahead of print]
|
|
|
|
|
|
14) Isakova T, Gutiérrez OM, Smith K, et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant. 2010. Jul 14[Epub ahead of print]
|
|
|
|
|